The shares of pharmaceutical companies Glaxo Smith Kline (GSK.UK) and Sanofi (SAN.FR) rose today amid reports from Bloomberg that thousands of lawsuits over the drug Zantac have been dismissed. Concerns had been weighing on pharmaceutical company stock valuations for several months. Also gaining on the wave of reports are Haleon (HLN.UK) and Pfizer, which is trading slightly higher in opening trade (PFE.US):
- Zantac was used as a popular prescription heartburn drug for nearly a decade. The Federal Drug Administration (FDA) took it off the market in 2020 amid concerns about the consequences of its use. Since then, thousands of people have sued companies that sold the drug, claiming it caused cancer;
- In a ruling issued Tuesday in federal court in Florida, however, Judge Robin Rosenberg wrote that scientists do not support the claims. Â Ultimately, the court found that there was no evidence that Zantac caused the cancers it was accused of causing;
- The likelihood that companies will have to make substantial liability payments for Zantac has dropped significantly. In a statement reported by Reuters, attorneys for the plaintiffs in the suit said they expect the judge's decision to be reversed on appeal. Investors paid little attention to the Zantac-related dispute until August, when UBS analysts began talking about the case;
- Haleon, formerly a joint venture of Pfizer and GSK, which sold the Zantac drug at various times, said it would not be financially liable even if its two predecessor companies were found liable in lawsuits over the matter.
Glaxo Smith Kline (GSK.UK) stock chart, D1 interval. Glaxo Smith Kline shares opened today with an upward gap. Sanofi (SAN.FR, yellow chart) shares also reacted euphorically to the reports. Source: xStation5
Kezdjen befektetni még ma, vagy próbålja ki ingyenes demónkat
ĂlĆ szĂĄmla regisztrĂĄciĂł DEMĂ SZĂMLA Mobil app letöltĂ©se Mobil app letöltĂ©seEzen tartalmat az XTB S.A. kĂ©szĂtette, amelynek szĂ©khelye VarsĂłban talĂĄlhatĂł a következĆ cĂmen, Prosta 67, 00-838 VarsĂł, LengyelorszĂĄg (KRS szĂĄm: 0000217580), Ă©s a lengyel pĂ©nzĂŒgyi hatĂłsĂĄg (KNF) felĂŒgyeli (sz. DDM-M-4021-57-1/2005). Ezen tartalom a 2014/65/EU irĂĄnyelvĂ©nek, ami az EurĂłpai Parlament Ă©s a TanĂĄcs 2014. mĂĄjus 15-i hatĂĄrozata a pĂ©nzĂŒgyi eszközök piacairĂłl , 24. cikkĂ©nek (3) bekezdĂ©se , valamint a 2002/92 / EK irĂĄnyelv Ă©s a 2011/61 / EU irĂĄnyelv (MiFID II) szerint marketingkommunikĂĄciĂłnak minĆsĂŒl, tovĂĄbbĂĄ nem minĆsĂŒl befektetĂ©si tanĂĄcsadĂĄsnak vagy befektetĂ©si kutatĂĄsnak. A marketingkommunikĂĄciĂł nem befektetĂ©si ajĂĄnlĂĄs vagy informĂĄciĂł, amely befektetĂ©si stratĂ©giĂĄt javasol a következĆ rendeleteknek megfelelĆen, Az EurĂłpai Parlament Ă©s a TanĂĄcs 596/2014 / EU rendelete (2014. ĂĄprilis 16.) a piaci visszaĂ©lĂ©sekrĆl (a piaci visszaĂ©lĂ©sekrĆl szĂłlĂł rendelet), valamint a 2003/6 / EK eurĂłpai parlamenti Ă©s tanĂĄcsi irĂĄnyelv Ă©s a 2003/124 / EK bizottsĂĄgi irĂĄnyelvek hatĂĄlyon kĂvĂŒl helyezĂ©sĂ©rĆl / EK, 2003/125 / EK Ă©s 2004/72 / EK, valamint az (EU) 2016/958 bizottsĂĄgi felhatalmazĂĄson alapulĂł rendelet (2016. mĂĄrcius 9.) az 596/2014 / EU eurĂłpai parlamenti Ă©s tanĂĄcsi rendeletnek a szabĂĄlyozĂĄsi technikai szabĂĄlyozĂĄs tekintetĂ©ben törtĂ©nĆ kiegĂ©szĂtĂ©sĂ©rĆl a befektetĂ©si ajĂĄnlĂĄsok vagy a befektetĂ©si stratĂ©giĂĄt javaslĂł vagy javaslĂł egyĂ©b informĂĄciĂłk objektĂv bemutatĂĄsĂĄra, valamint az egyes Ă©rdekek vagy összefĂ©rhetetlensĂ©g utĂĄni jelek nyilvĂĄnossĂĄgra hozatalĂĄnak technikai szabĂĄlyaira vonatkozĂł szabvĂĄnyok vagy egyĂ©b tanĂĄcsadĂĄs, ideĂ©rtve a befektetĂ©si tanĂĄcsadĂĄst is, az A pĂ©nzĂŒgyi eszközök kereskedelmĂ©rĆl szĂłlĂł, 2005. jĂșlius 29-i törvĂ©ny (azaz a 2019. Ă©vi Lap, mĂłdosĂtott 875 tĂ©tel). Ezen marketingkommunikĂĄciĂł a legnagyobb gondossĂĄggal, tĂĄrgyilagossĂĄggal kĂ©szĂŒlt, bemutatja azokat a tĂ©nyeket, amelyek a szerzĆ szĂĄmĂĄra a kĂ©szĂtĂ©s idĆpontjĂĄban ismertek voltak , valamint mindenfĂ©le Ă©rtĂ©kelĂ©si elemtĆl mentes. A marketingkommunikĂĄciĂł az ĂgyfĂ©l igĂ©nyeinek, az egyĂ©ni pĂ©nzĂŒgyi helyzetĂ©nek figyelembevĂ©tele nĂ©lkĂŒl kĂ©szĂŒl, Ă©s semmilyen mĂłdon nem terjeszt elĆ befektetĂ©si stratĂ©giĂĄt. A marketingkommunikĂĄciĂł nem minĆsĂŒl semmilyen pĂ©nzĂŒgyi eszköz eladĂĄsi, felajĂĄnlĂĄsi, feliratkozĂĄsi, vĂĄsĂĄrlĂĄsi felhĂvĂĄsĂĄnak, hirdetĂ©sĂ©nek vagy promĂłciĂłjĂĄnak. Az XTB S.A. nem vĂĄllal felelĆssĂ©get az ĂgyfĂ©l ezen marketingkommunikĂĄciĂłban foglalt informĂĄciĂłk alapjĂĄn tett cselekedeteiĂ©rt vagy mulasztĂĄsaiĂ©rt, kĂŒlönösen a pĂ©nzĂŒgyi eszközök megszerzĂ©sĂ©Ă©rt vagy elidegenĂtĂ©sĂ©Ă©rt. Abban az esetben, ha a marketingkommunikĂĄciĂł bĂĄrmilyen informĂĄciĂłt tartalmaz az abban megjelölt pĂ©nzĂŒgyi eszközökkel kapcsolatos eredmĂ©nyekrĆl, azok nem jelentenek garanciĂĄt vagy elĆrejelzĂ©st a jövĆbeli eredmĂ©nyekkel kapcsolatban.
